Certara, Inc. (NASDAQ:CERT) Position Trimmed by Riverbridge Partners LLC

Riverbridge Partners LLC trimmed its holdings in shares of Certara, Inc. (NASDAQ:CERT - Free Report) by 5.4% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,048,519 shares of the company's stock after selling 116,228 shares during the period. Riverbridge Partners LLC owned about 1.27% of Certara worth $20,280,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Versant Capital Management Inc lifted its position in Certara by 218.8% during the first quarter. Versant Capital Management Inc now owns 2,719 shares of the company's stock valued at $27,000 after buying an additional 1,866 shares in the last quarter. Venturi Wealth Management LLC lifted its position in shares of Certara by 839.1% during the fourth quarter. Venturi Wealth Management LLC now owns 2,808 shares of the company's stock worth $30,000 after purchasing an additional 2,509 shares in the last quarter. Wells Fargo & Company MN lifted its position in shares of Certara by 48.4% during the fourth quarter. Wells Fargo & Company MN now owns 3,208 shares of the company's stock worth $34,000 after purchasing an additional 1,047 shares in the last quarter. Johnson Financial Group Inc. acquired a new position in shares of Certara during the fourth quarter worth $47,000. Finally, ANTIPODES PARTNERS Ltd lifted its position in shares of Certara by 204.7% during the fourth quarter. ANTIPODES PARTNERS Ltd now owns 5,442 shares of the company's stock worth $58,000 after purchasing an additional 3,656 shares in the last quarter. 73.96% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the stock. TD Cowen assumed coverage on shares of Certara in a research report on Thursday, February 27th. They set a "buy" rating and a $16.00 target price on the stock. Robert W. Baird boosted their target price on shares of Certara from $9.00 to $13.00 and gave the stock a "neutral" rating in a research report on Friday, April 11th. KeyCorp boosted their target price on shares of Certara from $15.00 to $18.00 and gave the stock an "overweight" rating in a research report on Wednesday, April 16th. Barclays raised shares of Certara from an "equal weight" rating to an "overweight" rating and boosted their target price for the stock from $11.00 to $14.00 in a research report on Thursday, May 8th. Finally, William Blair reissued a "market perform" rating on shares of Certara in a research report on Thursday, February 27th. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $15.67.

Certara Stock Down 0.8%

CERT traded down $0.08 during trading on Monday, hitting $10.46. The company had a trading volume of 1,556,232 shares, compared to its average volume of 1,415,158. The company has a market cap of $1.70 billion, a PE ratio of -523.00 and a beta of 1.45. The business has a 50-day moving average of $12.17 and a 200-day moving average of $11.86. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.78 and a quick ratio of 2.78. Certara, Inc. has a 1-year low of $8.64 and a 1-year high of $16.93.

Certara (NASDAQ:CERT - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.10 by $0.04. The firm had revenue of $106.00 million for the quarter, compared to analysts' expectations of $104.44 million. Certara had a negative net margin of 0.67% and a positive return on equity of 5.05%. The firm's quarterly revenue was up 9.7% on a year-over-year basis. During the same period in the prior year, the company posted $0.10 earnings per share. As a group, analysts forecast that Certara, Inc. will post 0.28 earnings per share for the current year.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.